Analysis of skeletal-related events in breast cancer and response to therapy

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 22-27

  LoRusso, Patricia ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0034852321     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25437     Document Type: Conference Paper

References (12)

1. Skeletal complications of malignancy
2. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
3. Current use of bisphosphonates in oncology
4. Pamidronate disodium in the treatment and management of hypercalcemia
5. Pathogenesis and management of cancerassociated hypercalcaemia
6. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
7. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomised, placebocontrolled trial
8. Hypercalcemia of malignancy in the palliative care patient: A treatment strategy
9. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound
10. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
11. Zoledronic acid reduces skeletal related events in patients with osteolytic metastases
12. Biochemical markers and skeletal metastases